Marksans Pharma Ltd (MARKSANS) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Marksans Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Allotment of Equity Shares under Marksans Employees Stock Option Scheme 2024
Others (Uncategorized) · 04 Nov 2026, 10:26 pm
Marksans Pharma Allots 56,250 Equity Shares Under ESOP Scheme 2024 Marksans Pharma Limited announced that its Nomination and Remuneration Committee approved the allotment of 56,250 fully paid-up equity shares (face value Re. 1 each) on 4th Nov'26. The allotment was executed upon the exercise of vested options by eligible grantees under the Marksans Employees Stock Option Scheme 2024. The newly issued equity shares will rank pari passu with the company's existing equity shares across all respects.
Press Release for Financial Results Q2FY27
Press Release · 04 Nov 2026, 7:12 pm
Marksans Pharma Posts Record Q2FY27 Results With 48% EBITDA Surge Marksans Pharma reported a 30.5% YoY rise in consolidated operating revenue to Rs. 940.2 cr in Q2FY27, driven by strong growth in UK & Europe (+64.9% YoY to Rs. 404.6 cr) and the US (+8.7% YoY to Rs. 420.9 cr). EBITDA grew 48.3% YoY to Rs. 214.3 cr with margins expanding 274 bps to 22.8%. PAT rose 44.8% YoY to Rs. 143.5 cr. In H1FY27, PAT surged 92.5% YoY to Rs. 302.9 cr, operating cash flow jumped 4.3x to Rs. 322 cr, and net cash stood at Rs. 1,095 cr.
Investor Presentation Q2FY27
Investor Presentation · 04 Nov 2026, 7:10 pm
Marksans Pharma Delivers Robust Q2FY27 Growth Driven by Core Markets Marksans Pharma posted strong Q2FY27 operating revenue of ₹940.2 cr, up 30.5% YoY (25% organic), supported by 64.9% growth in UK & Europe and solid US traction. EBITDA rose 48.3% YoY to ₹214.3 cr, with margins expanding 274 bps to 22.8% on operating leverage, while PAT reached ₹143.5 cr (+44.8% YoY). H1FY27 operating cash flow surged 4.3x to ₹322 cr, leaving a net cash balance of ₹1,095 cr as of 30th Sep'26. TTM ROCE improved significantly to 24.7%.
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 2026
Financial Result · 04 Nov 2026, 7:05 pm
Marksans Pharma Reports Robust Q2 FY27 Consolidated Revenue Growth and Net Profit Expansion Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 million for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 million and 11.8% QoQ. Consolidated net profit attributable to owners rose 43.8% YoY to ₹1,413.12 million (₹982.50 million in Q2 FY26), with basic EPS improving to ₹3.12 from ₹2.17. For H1 FY27, operating revenue reached ₹17,809.65 million with PAT at ₹2,984.79 million. Inorganic European expansion continued via 100% acquisitions of Netherlands-based QliniQ B.V. (€7.50 million) and Germany-based ABCnow GmbH (€1.10 million).
Marksans Pharma Limited has submitted to the Exchange, unaudited financial results for the quarter and half year ended September 30, 2026.
Outcome · 04 Nov 2026, 7:04 pm
Marksans Pharma Reports Robust Q2 FY27 Consolidated Results Alongside Key European Acquisitions Marksans Pharma posted consolidated revenue from operations of ₹9,401.69 mn for the quarter ended 30th Sep'26, up 30.5% YoY from ₹7,204.09 mn and 11.8% QoQ. Consolidated net profit attributable to owners reached ₹1,413.12 mn versus ₹982.50 mn in Q2 FY26 (up 43.8% YoY). For H1 FY27, revenue rose 32.8% YoY to ₹17,809.65 mn with PAT of ₹2,984.79 mn. The company completed 100% acquisitions of Dutch distributor QliniQ B.V. for EUR 7.50 mn and German-based ABCnow GmbH for EUR 1.10 mn.
Please find attached outcome of the Board meeting held on 04 November 2026
Outcome · 04 Nov 2026, 6:57 pm
Marksans Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 9,402 (+30.5% YoY | +11.8% QoQ) ■ EBITDA: 2,143 (+48.3% YoY | +0.6% QoQ) ■ EBITDA Margin (%): 22.8 (+274 bps YoY | -254 bps QoQ) ■ PAT: 1,413 (+43.8% YoY | -10.1% QoQ) ■ EPS (INR): 3.11 (+43.3% YoY | -10.4% QoQ)
Intimation of schedule for Q2FY27 Earnings Conference Call
Intimation · 05 Nov 2026, 4:00 pm
Marksans Pharma Schedules Q2FY27 Earnings Conference Call for 5th Nov'26 Marksans Pharma Ltd. has scheduled its Q2FY27 earnings conference call on 5th Nov'26 at 04:00 PM IST to discuss unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The call will be hosted by Systematix Institutional Equities, with executive representation from Founder, Chairman, and MD Mark Saldanha, alongside CFO Jitendra Sharma. Presentation materials, audio recordings, and transcripts will be made available on the company's official website post-event.
MARKSANS PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
To consider and approve the Unaudited Financial Results for the quarter and half year ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Intimation · 04 Nov 2026, 5:30 am
Marksans Pharma Board Meeting Scheduled for November 4, 2026 Marksans Pharma Ltd. announced that its Board of Directors will meet on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company shares by designated persons and their immediate relatives has been closed from 1st Oct'26 and will remain closed until 6th Nov'26, 48 hours post the financial results announcement.
Notice to Shareholders regarding re-opening of Special Window for Re-lodgement of transfer requests of Physical Shares
Others (Uncategorized) · 17 Sept 2026, 7:50 pm
Marksans Pharma Opens Special Window for Physical Share Transfer Re-lodgment Following SEBI guidelines, Marksans Pharma Ltd. announced the opening of a one-year special window from 5th Feb'26 to 4th Feb'27 for re-lodging physical share transfer deeds. This applies to shares transacted prior to 1st Apr'19 that were previously rejected or unaddressed due to documentation deficiencies. Approved transfers will be credited exclusively in demat mode and subject to a mandatory one-year lock-in period, barring any transfer, pledge, or lien. Disputed cases and shares transferred to IEPF remain excluded from this process.
Intimation of schedule of Investors Meet
Intimation · 01 Sept 2026, 11:51 pm
Marksans Pharma to Participate in Investor Conference Marksans Pharma will participate in the Ashwamedh - Elara India Dialogue 2026 on 02nd Sep'26. The company will hold a physical group meeting with investors and analysts at the Hyatt in Santacruz East, Mumbai. Management has stated that no unpublished price-sensitive information will be disclosed during the event. The schedule is subject to potential changes.
Please find attached the voting result of the 34th AGM
Annual General Meeting · 28 Aug 2026, 12:27 am
Scrutinizer''s Report along with voting result for the 34th AGM
Annual General Meeting · 28 Aug 2026, 12:21 am
Proceeding of 34th Annual General Meeting of the Company held today
Annual General Meeting · 27 Aug 2026, 8:30 pm
Please find attached disclosure on ESG rating
Others (Uncategorized) · 26 Aug 2026, 9:46 pm
Marksans Pharma Receives ESG Score from CRISIL Ratings Marksans Pharma announced on 26th Aug'26 that it has received an ESG Score of "56" from Crisil ESG Ratings & Analytics Ltd. The voluntary review was based on publicly available data for Fiscal 2026. Crisil is a SEBI Licensed ESG Rating Provider. The disclosure was made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements.
Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results
Transcript · 20 Aug 2026, 5:12 pm
Audio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results
Audio / Video · 14 Aug 2026, 12:15 am
Marksans Pharma Discloses Q1FY27 Investor Call Audio Recording Marksans Pharma informed stock exchanges that it has uploaded the audio recording of its investor and analyst conference call for Q1FY27 financial results. The call was held on 13 Aug'26, and the recording is now available on the company's website. This action complies with SEBI's disclosure requirements.
Press Release for Financial Results Q1 FY 27
Press Release · 12 Aug 2026, 6:02 pm
Marksans Pharma Reports Record Q1FY27 Profitability and Strong Revenue Growth Marksans Pharma posted strong Q1FY27 results, with revenue up 35.6% YoY to ₹841 cr. Profitability hit all-time highs as EBITDA surged 112.8% YoY to ₹213 cr and PAT grew 173.9% YoY to ₹159 cr. EBITDA margin expanded significantly by 919 bps to 25.3%. The UK & Europe segment was a key driver, with revenue up 74.7% YoY to ₹356 cr, including a ₹44 cr contribution from the new QliniQ acquisition. The US market grew 15.1% YoY. The company's cash balance crossed ₹1,000 cr, ending the quarter at ₹1,058 cr.
Investor Presentation Q1 FY 27
Investor Presentation · 12 Aug 2026, 6:00 pm
Marksans Pharma Q1FY27: Record EBITDA and European Expansion Drive Strong Growth Marksans Pharma posted strong Q1FY27 results with revenue up 35.6% YoY to ₹841 cr and PAT surging 173.9% to ₹159 cr. EBITDA hit an all-time high of ₹213 cr, growing 112.8% YoY, with margins expanding 919 bps to 25.3% due to operating leverage and favorable mix. Growth was broad-based, led by UK & Europe (+74.7% YoY) which benefited from the QliniQ acquisition contributing ₹44 cr. The company crossed ₹1,000 cr in cash balance, closing the quarter at ₹1,058 cr, strengthening its position for future growth.
The Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30, 2026
Financial Result · 12 Aug 2026, 5:54 pm
Marksans Pharma Q1FY27: Strong YoY Profit Growth Amidst European Acquisitions Marksans Pharma reported strong Q1FY27 consolidated results with net profit rising 170% YoY to ₹1,594.1M and revenue up 35.6% YoY to ₹8,408.0M. However, on a sequential basis, revenue declined 1.8% and profit grew 6.9%. The company acquired Netherlands-based QliniQ B.V. for EUR 7.50M during the quarter. Post-quarter, it completed the acquisition of Germany-based ABCnow GmbH for EUR 1.10M, strengthening its European presence. Basic EPS for the quarter was ₹3.47, up from ₹1.29 in the prior year quarter.
The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2026
Outcome · 12 Aug 2026, 5:49 pm
Marksans Pharma Q1FY27: Strong YoY Growth Driven by Revenue and Profit Expansion Marksans Pharma reported robust Q1FY27 consolidated results with net profit rising 170.4% YoY to ₹1,594.07 million on revenue growth of 35.6% YoY to ₹8,407.96 million. Sequentially, revenue declined by 1.8% QoQ while net profit increased by 7.0% QoQ. Profit before tax stood at ₹2,065.71 million, up 169.7% YoY. Diluted EPS for the quarter was ₹3.47, a significant increase from ₹1.29 in Q1FY26. During the quarter, the company acquired Netherlands-based QliniQ B.V. for EUR 7.50 million.
Please find enclosed the BRSR
Others (Uncategorized) · 04 Aug 2026, 5:17 pm
Marksans Pharma Submits Business Responsibility and Sustainability Report for FY25-26 Marksans Pharma submitted its Business Responsibility and Sustainability Report for FY25-26 on 04 Aug'26. The company's business, which is 100% pharmaceutical formulations, derives its entire turnover from exports to over 50 countries. For FY26, the company reported nil complaints across key stakeholder groups including investors, customers, and employees. The permanent employee turnover rate was 22.29%, up from 15.32% in FY25. The company's board consists of 8 directors, with 25% female representation. All RPTs for sales (90%) and investments (100%) were with subsidiaries.
Please find attached herewith the Annual Report for the Financial Year 2025-26
Others (Uncategorized) · 04 Aug 2026, 5:03 pm
Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 2026
Annual General Meeting · 04 Aug 2026, 4:49 pm